Recruiting
Efficacy and Safety of HUC3-637 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
A multicenter, randomized, single-blind, active controlled, phase III clinical trial to evaluate the efficacy and safety of HUC3-637 in patients with primary open angle glaucoma or ocular hypertension
ClinicalTrials.gov IDNCT07335211
PhasePHASE3
Enrollment206
SponsorHuons Co., Ltd.
Age19 Years
SexALL
Conditions studied
Primary Open Angle Glaucoma (POAG), Ocular Hypertension
About this study
A multicenter, randomized, single-blind, active controlled, phase III clinical trial to evaluate the efficacy and safety of HUC3-637 in patients with primary open angle glaucoma or ocular hypertension
Interventions
- Drug: HUC3-637 — Ophthalmic solution instilled directly into the eye (topical ocular administration)
- Drug: HUC3-637-R — Ophthalmic solution instilled directly into the eye (topical ocular administration)
Primary outcomes
- Mean change in diurnal IOP (12 week)
Eligibility information
Inclusion Criteria:
* Adults aged 19 years and older
* Participants diagnosed with POAG or OH
* Have fully explained and understood the study and have voluntarily given written informed consent.
Exclusion Criteria:
* Acute or chronic angle-closure glaucoma
* Congenital glaucoma, secondary glaucoma (open-angle glaucoma)
Study locations
- Kangbuk Samsung Hospital, Seoul, South Korea
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.